David J. Kerr

4.9k total citations · 1 hit paper
38 papers, 2.4k citations indexed

About

David J. Kerr is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, David J. Kerr has authored 38 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in David J. Kerr's work include Cancer Research and Treatments (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Virus-based gene therapy research (5 papers). David J. Kerr is often cited by papers focused on Cancer Research and Treatments (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Virus-based gene therapy research (5 papers). David J. Kerr collaborates with scholars based in United Kingdom, United States and Norway. David J. Kerr's co-authors include Lawrence S. Young, D. Ferry, Michael J.O. Wakelam, Matthew N. Hodgkin, Allison Stewart, Michael Cross, Nicholas A. Wright, Alan G. Casson, Janusz Jankowski and George Triadafilopoulos and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

David J. Kerr

37 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study

2020 393 citations David J. Kerr et al. profile →

Peers

David J. Kerr

ONCOL

SURGE

RNMI

PRM

Masahiro Takada Japan

Molly Brewer United States

Zhenli Li China

Chryso Kanthou United Kingdom

Rajamanickam Baskar Singapore

Joseph Ciccolini France

Adrienne G. Waks United States

Janice Tsang Hong Kong

Zhikun Liu China

Masahiro Takada Japan

David J. Kerr

370 ×0.5

ONCOL

706 ×0.9

154 ×0.4

SURGE

412 ×1.3

RNMI

158 ×0.5

PRM

Citations per year, relative to David J. Kerr David J. Kerr (= 1×) peers Masahiro Takada

Countries citing papers authored by David J. Kerr

Since Specialization

Citations

This map shows the geographic impact of David J. Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Kerr more than expected).

Fields of papers citing papers by David J. Kerr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Kerr. The network helps show where David J. Kerr may publish in the future.

Co-authorship network of co-authors of David J. Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Kerr. A scholar is included among the top collaborators of David J. Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Kerr. David J. Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bell, David & David J. Kerr. (2015). Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opinion on Drug Metabolism & Toxicology. 11(9). 1341–1344. 4 indexed citations

Kerr, David J., Janet Dunn, M. J. S. Langman, et al.. (2007). Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. New England Journal of Medicine. 357(4). 360–369. 95 indexed citations

Maruta, Fukuto, Jun Nakayama, Shinichi Miyagawa, et al.. (2007). Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of drug targeting. 15(4). 311–319. 6 indexed citations

Palmer, Daniel H., Mei‐Jou Chen, Peter F. Searle, David J. Kerr, & Lawrence S. Young. (2005). Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Therapy. 12(15). 1187–1197. 11 indexed citations

Danson, Sarah, D. Ferry, Valery Yu. Alakhov, et al.. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. 90(11). 2085–2091. 298 indexed citations

Palmer, Daniel H., Anne E. Milner, David J. Kerr, & Lawrence S. Young. (2003). Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. British Journal of Cancer. 89(5). 944–950. 26 indexed citations

Neoptolemos, John P., Janet Dunn, Jennifer Almond, et al.. (2001). Association of upper gastrointestinal surgeons of Great Britain and Ireland. British journal of surgery. 88(3). 475–475. 5 indexed citations

Thomson, Tina, Hing Y. Leung, Peter F. Searle, et al.. (2001). Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid Tumors. Molecular Therapy. 3(2). 233–240. 45 indexed citations

Mulholland, Paul, D. Ferry, David Anderson, et al.. (2001). Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology. 12(2). 245–248. 126 indexed citations

10.

Ferry, D., Mark Deakin, Simon R. Bramhall, et al.. (2000). A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology. 11(9). 1165–1170. 15 indexed citations

11.

Harper, Angela, David J. Kerr, Andreas Gescher, & James Kevin Chipman. (1999). Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. Free Radical Research. 31(2). 149–160. 64 indexed citations

12.

Anderson, David A., et al.. (1999). High-performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 731(2). 293–298. 3 indexed citations

13.

Young, Annie, et al.. (1999). Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?. Clinical Pharmacokinetics. 36(6). 391–398. 33 indexed citations

14.

Jankowski, Janusz, Nicholas A. Wright, Stephen J. Meltzer, et al.. (1999). Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the Esophagus. American Journal Of Pathology. 154(4). 965–973. 319 indexed citations

15.

Guest, Peter, et al.. (1997). Spontaneous pneumothorax associated with expectoration of a lump of metastatic renal cancer. Clinical Oncology. 9(4). 262–263. 8 indexed citations

16.

Helsby, Nuala A., John G Williams, David J. Kerr, Andreas J. Gescher, & James Kevin Chipman. (1997). The isoflavones equol and genistein do not induce xenobiotic-metabolizing enzymes in mouse and in human cells. Xenobiotica. 27(6). 587–596. 36 indexed citations

17.

Cross, Michael, Matthew N. Hodgkin, Jane A. Plumb, et al.. (1997). Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1362(1). 29–38. 3 indexed citations

18.

Cross, Michael, Allison Stewart, Matthew N. Hodgkin, David J. Kerr, & Michael J.O. Wakelam. (1995). Wortmannin and Its Structural Analogue Demethoxyviridin Inhibit Stimulated Phospholipase A2 Activity in Swiss 3T3 Cells. Journal of Biological Chemistry. 270(43). 25352–25355. 238 indexed citations

19.

Jodrell, Duncan I., Wolfgang Oster, David J. Kerr, et al.. (1994). A phase I–II study of N-(phosphonacetyl)-l-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. European Journal of Cancer. 30(7). 950–954. 2 indexed citations

20.

Zoumpourlis, Vassilis, David J. Kerr, & Demetrios�� Spandidos. (1991). Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. Cancer Letters. 56(2). 181–185. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact